Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC

October 5th 2023

The FDA has approved the CRCdx® RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer, according to an announcement from EntroGen.

Japanese Approval Sought for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

October 2nd 2023

A new drug application seeking the approval of fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer has been submitted to Japan’s Ministry of Health, Labour, and Welfare.

Dr Jones on the Application of ctDNA Testing in CRC

September 29th 2023

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

September 22nd 2023

Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer

IDEA Collaboration Affects Choice of Chemotherapy Regimen, Treatment Duration in Stage III Colon Cancer

September 18th 2023

Although findings from the International Duration Evaluation of Adjuvant Therapy collaboration in 2018 failed to demonstrate the noninferiority of 3 months of adjuvant chemotherapy vs 6 months for patients with stage III colon cancer, clinically relevant data in subgroup analyses have influenced practice prescribing patterns, according to a retrospective analysis.

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

September 13th 2023

The integration of novel mRNA biomarkers into the ColoAlert® screening test resulted in high sensitivity and specificity for colorectal cancer.

Dr Fakih on the Significance of the PROSPECT Trial in Rectal Cancer

September 12th 2023

Marwan G. Fakih, MD, expands on long-term findings from the phase 2/3 PROSPECT trial and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.

Dr Hochster on the FRESCO-2 Trial in mCRC

September 6th 2023

Howard S. Hochster, MD, discusses data from the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care in metastatic colorectal cancer.

Dr Li on the Evolution of HER2-Targeted Therapy in HER2+ CRC

September 5th 2023

Daneng Li, MD, discusses the evolution of treating patients with HER2-positive colorectal cancer and highlights the effects of implementing HER2-targeted therapy in this patient population.

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

August 31st 2023

The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Thierry André, MD, discusses the investigation of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer, including how its use as a standard of care in the third line supported its investigation in the first-line setting, the regimen’s efficacy and safety in the SOLSTICE trial, and the importance of this combination for patients in this space despite negative trial results.

FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

August 29th 2023

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

August 26th 2023

Circulating tumor DNA status at the time of postoperative minimal residual disease assessment was found to be a prognostic factor for disease-free survival in patients with radically resected stage II to IV colorectal cancer.

PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

August 23rd 2023

Michael Cecchini, MD, expands on key updates in gastrointestinal cancer from the 2023 ASCO Annual Meeting, including the clinical significance of findings from the PROSPECT and phase 3 PRODIGE 23 trials of perioperative chemotherapy vs selective standard chemoradiation.

Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers

August 22nd 2023

Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.

HER2 Amplification Shows Prognostic Capabilities in mCRC

August 22nd 2023

HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.

Recent Updates in Early Onset Colorectal Cancer: What We Know and Where to Go

August 22nd 2023

Oncologists globally explore trends, challenges in diagnosis, and future directions in patients with colorectal cancer.

Dr Fakih on the BASECAMP-1 Study in HLA-A*0201-Positive Solid Tumors

August 21st 2023

Marwan G. Fakih, MD, discusses the main objective and design of the observational BASECAMP-1 study and how it functions alongside the phase 1/2 EVEREST-1 study in patients with solid tumors.

Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC

August 18th 2023

Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.

Dr Kopetz on the Investigation of Encorafenib, Cetuximab, and Chemotherapy in mCRC

August 16th 2023

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.